Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06494241
Active, not recruiting Observational

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

NCT06494241 · tracked via the Priya Life Science China tracker
Sponsor
AstraZeneca
Phase
Observational
Started
2024-11-22
Last updated
2026-09-29

Condition(s) studied

Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Study summary

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years, at the time of signing the informed consent. * ECOG performance status 0-2. * Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC. Exclusion Criteria: * Be participating in other intervention clinical trials. * Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. * Previous enrolment in the other QIP study.

Primary outcome measure(s)

  • To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP — Approximately 1 month after last patient in
    Molecular testing-rate for the first-line treatment: Defined as the number of participants received molecular testing for the first-line treatment divided by total participants.
  • To evaluate the treatment pattern in metastatic NSCLC patients after QIP — Approximately 1 month after last patient in
    TKIs first-line treatment rate: Defined as TKIs first-line treatment rate in AGA positive participants.

Trial sites (46)

FacilityCityRegionStatus
Research Site Anning China
Research Site Anqing China
Research Site Changzhi China
Research Site Daqing China
Research Site Dazhou China
Research Site Dazhu China
Research Site Dingzhou China
Research Site Ganzhou China
Research Site Guangzhou China
Research Site Guang’an China
Research Site Hanzhong China
Research Site Hebi China
Research Site Hengyang China
Research Site Huaibei China
Research Site Jining China
Research Site Jinzhou China
Research Site Liyang China
Research Site Lu'an China
Research Site Meihekou China
Research Site Nanchong China
Research Site Nanyang China
Research Site Ningde China
Research Site Ningxiang China
Research Site Panjin China
Research Site Pingxiang China
Research Site Quanzhou China
Research Site Shengzhou China
Research Site Suzhou China
Research Site Taizhou China
Research Site Tancheng China
Research Site Tongling China
Research Site Wafangdian China
Research Site Weifang China
Research Site Wuzhou China
Research Site Xiangtan China
Research Site Xianning China
Research Site Xiantao China
Research Site Xixian China
Research Site Xuzhou China
Research Site Yangjiang China

+ 6 more sites — see the full list on the official registry below.

More AstraZeneca trials in China

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight Active, not recruiting
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations Active, not recruiting
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies Active, not recruiting
Study for AZD4360 in Participants With Advanced Solid Tumours Active, not recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors Recruiting

Other trials for the same condition

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Recruiting
Association of Psychological Distress in Patients With Lung Cancer Recruiting
CD70-targeted immunoPET Imaging of Kidney Cancer Recruiting
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors Active, not recruiting
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06494241 on ClinicalTrials.gov ↗ ← All trials in China